Latest Rhinitis Stories
ATLANTA and BRIDGEWATER, N.J. Sept. 8 /PRNewswire/ -- From cubbies and carpets to class pets and pollen, as parents prepare for this year's back to school they should also prepare for the upcoming fall allergy season.
SOMERSET, N.J., Sept. 2 /PRNewswire/ -- Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR).
KENILWORTH, N.J., Aug.
NAPLES, Fla., Aug. 26 /PRNewswire/ -- Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation.
FT. WASHINGTON, Pa., Aug. 25 /PRNewswire/ -- The makers of ZYRTEC(R), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., today announced the availability of two new allergy solutions to help adult and children allergy sufferers this fall allergy season.
NEW YORK, Aug. 18 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc.
NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- - Jingwei Capsules Treat Allergy Symptoms - - Complements Established Boke Nasal Spray Brand - - Diversifies Product Offering with Capsule Formulation - American Oriental Bioengineering, Inc.
KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S.
Asthma and allergy sufferers have an alternative to Singulair and Zicam - The ALCAT Test WARSAW, Poland, June 22 /PRNewswire/ -- Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular leukotriene blocking asthma and allergy drug, to upgrade their warning against psychotic side effects.
Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- A poem in which the author retracts something said in an earlier poem.